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teins, including the presence of two transmembrane domains (TMs) and two nucleotide-binding domains (NBDs) (29) . CFTR also possesses a regulatory domain (R-D), a unique feature among ABC proteins (28) . Activation of CFTR anion transport requires phosphorylation of the R-D by PKA and PKC, as well as dimerization of the two NBDs (16) , although the precise mechanism has not yet been described. Binding and hydrolysis of ATP at the NBD dimer interface is thought to induce a conformational change in the channel pore through interactions between the NBD and TM domains (10, 33, 36) , allowing the passage of chloride ions and bicarbonate (9) through the plasma membrane.
There are over 1,500 mutations of CFTR known to cause CF. Some of these mutations exclusively compromise activation of CFTR expressed at the cell surface. Patients with these types of CFTR mutations would be expected to benefit greatly from agents that restore activity, including direct activators of the channel or agents that augment endogenous regulatory mechanisms. Several compounds discovered in high-throughput screening (HTS) that increase CFTR activity on a rapid timescale (Ͻ30 min) have been proposed as CFTR gating modulators. In this study we refer to acute CFTR modulators as gating "activators" (compounds whose administration alone induces CFTR gating) and CFTR "potentiators" (compounds that augment CFTR gating in response to cAMP signaling). These acute modulators include VX-770, a CFTR potentiator shown to restore CFTR activity and improve pulmonary function in G551D-CFTR CF patients (1, 40) . These agents may also be applicable to the most common mutation, deletion of phenylalanine at position 508 (F508del), found in 90% of CF individuals. The F508del-CFTR product primarily results in misfolded protein that is subject to elimination during cell processing, resulting in severely reduced expression at the plasma membrane. F508del-CFTR resident at the cell surface also exhibits abnormal cAMP-dependent regulation (5) , and defective channel gating (11, 43) . Therapeutic approaches intended to correct F508del-CFTR misprocessing by correcting F508del-CFTR misfolding, altering protein chaperones, or addressing other targets (e.g., "correctors") are under development (25, 40, 41) but are likely to also require rapidly acting modulators to restore F508del-CFTR channel function at the cell surface to clinically relevant levels (41) . A better understanding of how acutely acting CFTR modulators promote CFTR activity would allow compounds to be categorized functionally, rationally prioritized for clinical evaluation, and may lead to new insights regarding the activation and regulation of CFTR.
In this paper we describe distinct mechanisms of action underlying CFTR activation by acutely active compounds, distinguished by the induction of R-D phosphorylation. We developed a Western blot assay that allows the R-D phosphorylation status to be determined, without radioactivity or obfuscation by CFTR glycosylation status. We found that the isoxazole UC CF -152 [3-(2-benzyloxy-phenyl)-5-chloromethyl-isoxazole] induced PKA-dependent phosphorylation of the R-D and commensurate activation of wild-type (WT)-, G551D-, and surface localized F508del-CFTR, suggesting that it primarily acts as a CFTR activator. In contrast, the compound VRT-532 [4-methyl-2-(5-phenyl-1H-pyrazol-3-y)phenol], a pyrazole, primarily augmented cAMP-dependent regulation of CFTR, without evidence of R-D phosphorylation. These data reveal at least two classes among compounds capable of rapidly augmenting CFTR activity. Furthermore, activation of mutant CFTR is possible by a mechanism independent of R-D phosphorylation and is also well suited to restore regulation of CFTR-dependent chloride transport through endogenous (cAMP-dependent) activation pathways, a characteristic shown to be efficacious in the clinical setting (1).
MATERIALS AND METHODS
Ethical approval. The University of Alabama at Birmingham institutional review board approved use of cell lines employed in these studies.
Reagents. CFTR modulators were obtained from the publicly available CFTR modulator library [Dr. Robert J. Bridges, Rosalind Franklin University, Chicago, IL and Cystic Fibrosis Foundation Therapeutics (CFFT), Bethesda, MD] [http://www.cftrfolding.org (July 7, 2009)], and Exclusive Chemistry. All compounds were dissolved at 1,000ϫ in dimethyl sulfoxide (DMSO) and stored at Ϫ80°C.
Constructs. The cDNA for human CFTR R-D (residues 635-836) with the addition of a carboxy-terminal hemagglutinin (HA) tag was inserted into pcDNA3.1 (Invitrogen), and the identity of the construct confirmed via DNA sequencing. A retroviral vector was constructed by subcloning the HA-tagged R-D cDNA into pMXpie (provided by Dr. Alice Mui, Jack Bell Research Centre). This vector drives expression of enhanced green fluorescent protein from an internal ribosomal entry site downstream of the R-D cDNA and features a puromycin resistance gene governed by a separate promoter.
Cell lines and cell culture. HA-tagged CFTR R-D was expressed in HEK293, COS7, or NIH-3T3 cells. BOSC23 virus packaging cells and NIH-3T3 fibroblast cells were cultured in DMEM with penicillin (100 U/ml), streptomycin (50 U/ml), and 10% fetal calf serum. NIH-3T3 cells were retrovirally transduced by incubation with supernatants from BOSC23 cells that had been transiently transfected with pMXpie-RD constructs in the presence of 10 g of Polybrene/ml, as previously described (14) . Infected cells were selected in puromycin (2 g/ml).
CFBE41o Ϫ cells stably expressing WT-and F508del-CFTR following lentiviral transduction were maintained in DMEM/F12 medium (Invitrogen) with 10% fetal calf serum (5) . Fischer rat thyroid (FRT) cells stably transduced with WT-, F508del-, or G551D-CFTR cDNA (expression driven by a cytomegalovirus promoter) were a gift from Dr. Luis Galietta (G551D; Gaslini Institute, Genoa, Italy) or Dr. Joseph Zabner (WT and F508del; University of Iowa, Iowa City, IA), and maintained in minimal essential media with penicillin (100 U/ml), streptomycin (50 U/ml), 10% fetal calf serum, 1% L-glutamine, and 25 mM NaHCO3
(with the addition of 600 g/ml zeocin to maintain G551D selection). Cells were maintained in a 37°C humidified incubator in 5% CO 2 except where otherwise specified.
R-D phosphorylation and Western blotting. Cells expressing HAtagged R-D were treated with potentiator or vehicle (DMSO) for 20 min unless otherwise specified. Forskolin (20 M) treatments were for 5 min and H89 (10 M) pretreatment for 20 min. Potentiator treatments were at the previously published EC 50 (VRT-532, 5 M; UC CF-152, 50 M; PG-01, 300 nM; SF-03, 30 nM; UCCF-853, 3 M; ⌬F508 act-02, 70 nM; genistein, 30 M; UCCF-029, 2 M; UCCF-180, 10 M) (7, 26, 32, 37, 41, 51) , except where otherwise specified. After drug treatment, cells were lysed in buffer (1% NP-40, 50 mM Tris·HCl, pH 7.5, 200 mM NaCl, 5 mM MgCl 2, 15% glycerol) with protease (Complete mini protease cocktail, Roche Diagnostics) and phosphatase inhibitors [Na 3VO4 (0.2 mM), NaF (10 mM), MoO4 (1 mM), and ␤-glycerophosphate (50 mM)]. Equal amounts of total cell lysate were combined with SDS loading buffer for Western blot analysis. For immunoprecipitation studies, 500 g of total cell lysate was rotated with 20 l anti-HA agarose affinity matrix (Roche) for 1 h at 4°C, washed with lysis buffer, and combined with SDS loading buffer. Samples were resolved via electrophoresis through a 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and visualized by transfer to nitrocellulose and immunoblot with antibody to the HA tag (Covance) or anti-phospho(Ser/Thr) PKA substrate antibody (Cell Signaling, Boston, MA). Phosphorylation of the R-D was visualized as a 2-to 4-kDa shift, as described previously (8) .
Ussing chamber analysis of epithelial cell monolayers. FRT and CFBE41o
Ϫ cells expressing F508del-, G551D-, or WT-CFTR were seeded on fibronectin-coated 0.4-m permeable supports (Costar, Bethesda, MD; 5 ϫ 10 5 cells/filter, 6.5 mm diameter), grown to confluence, transferred to an air-liquid interface until high (Ͼ1,000 ⍀/cm 2 ) resistance was achieved, and mounted in modified Ussing chambers (Jim's Instruments) under voltage-clamp conditions (5, 31) . Monolayers were bathed on both sides with Ringer solutions containing 115 mM NaCl, 25 mM NaHCO3, 2.4 mM KH2PO4, 1.24 mM K2HPO4, 1.2 mM CaCl2, 1.2 mM MgCl2, and 10 mM D-glucose (pH 7.4). Bath solutions were vigorously stirred and gassed with 95% O2-5% CO2, and maintained at 37°C. Short-circuit current (Isc) measurements were obtained by using an epithelial voltage clamp (University of Iowa Bioengineering). A 3-mV pulse of 1-s duration was imposed every 100 s to monitor resistance, which was calculated by using Ohm's law. To measure stimulated Isc, the mucosal bathing solution was changed to a low-Cl Ϫ solution (1.2 mM NaCl). Sodium gluconate (115 mM) was added, as well as 100 M amiloride to inhibit sodium transport. Acute modulators (UCCF-152, 50 M; VRT-532, 5 M), forskolin (2 M), and genistein (50 M) were added to the bathing solutions as indicated (minimum 5 min of observation at each concentration). Glibenclamide (200 M) or CFTRINH-172 (10 M) was added to the mucosal bathing solution at the end of experiments to block CFTR-dependent Isc as an additional control. To correct F508del-CFTR processing, monolayers were incubated at low temperature (27°C) for 48 h or exposed to Corr-4a (10 -20 M for 8 -24 h) (25) . At least four monolayers were evaluated per condition.
ELISA cAMP quantification. Cellular cAMP was measured by using an ELISA-based detection kit (Cayman Chemicals) as described previously (5) . Briefly, NIH-3T3 cells stably expressing R-D were grown on 35-mm dishes (ϳ2.5 ϫ 10 6 cells/dish), stimulated with agonist for 20 min (UCCF-152, 50 M; VRT-532, 5 M; forskolin, 20 M), and lysed in 0.1 M HCl, and the cAMP levels were quantified according to the manufacturer's instructions by the relative standard curve method.
FRET cAMP localization. For ratiometric fluorescence resonance energy transfer (FRET), HEK293 cells expressing a sensor construct that consists of part of the exchange protein activated by cAMP (EPAC) sandwiched between cyan and yellow fluorescent proteins (CFP-EPAC-YFP) were seeded on 35-mm glass-bottom dishes and grown for 24 -48 h, washed twice with HBSS, and mounted on an inverted Olympus microscope (IX51, U-Plan Fluorite 60 ϫ 1.25 NA oil-immersion objective). Images were recorded by using a cooled EM-CCD camera (Hamamatsu) and the system was controlled by Slidebook 4.2 software (Intelligent Imaging Innovations). The light source used was a 300-W xenon lamp with a neutral density filter. A JP4 CFP/YFP filter set was used for image capture (Chroma), which includes a 430/25-nm excitation filter, a double dichroic beam splitter, and two emission filters (470/30 nm for CFP and 535/30 nm for FRET emission) alternated by filter-change controller Lambda 10 -3 (Sutter Instruments, Novato, CA). Time-lapse images were captured with 100-to 300-ms exposure time and 1-min time intervals. After establishing the baseline, forskolin, P1, or P10 were added. Acquired fluorescent images were background subtracted and multiple regions of interest (10 -20) were selected (three to five cells) for data analysis by using a ratio module. The emission ratio image (CFP/ FRET) was generated at different time points from CFP and FRET emission of background subtracted cells. All calculations were performed by using the FRET module of the SlideBook 4.2 software (Intelligent Imaging). The cell images are presented in pseudocolor to highlight the changes in the ratio of CFP/FRET fluorescence intensity.
PP2A in vitro protein phosphatase assay. A colorimetric phosphatase activity assay kit (Millipore) was used to detect PP2A activity according to the manufacturer's instructions. In brief, purified PP2A was combined with pNPP serine/threonine assay buffer (50 mM Tris·HCl, 100 mM CaCl 2, pH 7.0; Millipore) and CFTR modulator. Diluted phosphopeptide (K-R-pT-I-R-R) in serine/threonine assay buffer (250 M) was added and then incubated for 15 min at 30°C. Malachite Green phosphate detection solution was added for 15 min incubation at 30°C. The relative absorbance was measured at ϭ 630 nm. Results are from three independent experiments, each performed in duplicate.
PDE4D in vitro enzymatic activity assay. Modulator compound effects on PDE4D hydrolytic activity were measured with the Malachite Green assay by using a commercially available kit (Biomol, Plymouth Meeting, PA). Hydrolytic activity is measured as phosphate release from cAMP. Enzymatically active, recombinant PDE4D protein derived from Escherichia coli (Biomol) was used in the assays. All inhibitors were dissolved in DMSO and then added to the assays at the indicated concentrations (the maximal concentration of DMSO was never more than 10%).
Statistics. For densitometry, I sc, and enzyme activity studies, descriptive statistics (mean, SD, and SE) and paired and unpaired t-tests were performed by use of GraphPad Prism and Microsoft Excel. Multiple comparisons were made by ANOVA, and Pearson's test was used to calculate correlation coefficients (SPSS). All statistical tests were two sided and were performed at a 5% significance level (i.e., ␣ ϭ 0.05). Error bars represent SE in all figures unless otherwise noted.
RESULTS

R-D phosphorylation status after treatment with CFTR modulator.
Compounds acutely augmenting CFTR activity may act by facilitating phosphorylation of the R-D. The assessment of such phosphorylation is limited by the large size and broad glycosylation-sensitive electrophoresis pattern of full-length CFTR, which interferes with the interpretation of mobility shift experiments. To more accurately measure phosphorylation-dependent events, we developed a phospho-assay system by which HA-tagged R-D of CFTR is expressed heterologously and tested in NIH-3T3 cells. To validate this assay, we analyzed the phosphorylation of the domain by forskolin, which is known to induce PKA-mediated phosphorylation of the CFTR R-D. Treatment of the cells with 20 M forskolin for 5 min resulted in a 2-to 4-kDa mobility shift of the R-D on Western blots (Fig. 1A) as described previously for isolated R-D (confirmed by ␥ 32 -ATP phosphorylation and functional analysis) (8, 22, 50) as well as for CFTR half-channel constructs that included the R-D (23) . Forskolin induced the production of high levels of cAMP (Fig. 1F) , and the phosphorylation of the R-D by forskolin was inhibited by pretreatment with the PKA inhibitor H89 (10 M for 20 min) (Fig. 1,  A, D, E) . Inhibition of PKA at 10 M (the in vivo IC 50 ) would be predicted to be incomplete but circumvent the nonspecificity exhibited by H89 (the only cell-permeable PKA inhibitor) at higher concentrations (12, 20) . The lower mobility band was confirmed to correspond with the phosphorylated R-D band using immunoprecipitation with phospho-Ser/Thr site-specific antibodies (Fig. 1C) .
We used this system to compare phosphorylation induced by nine acute CFTR modulators available through the CFFT Modulator Library, compared with the well-characterized CFTR modulator genistein as a control. Treatment of the cells with UC CF -152 (P Ͻ 0.005, n ϭ 7) or UC CF -029 (P Ͻ 0.05) resulted in enhanced R-D phosphorylation compared with the vehicle control (Fig. 1B) , with UC CF -152 levels of phosphorylation ϳ37% of that stimulated by forskolin and greater than phosphorylation levels stimulated by genistein. Several compounds (UC CF -853, UC CF -180, PG-01, ⌬F508act-02, and SF-03) elicited higher levels of R-D phosphorylation than vehicle, but these effects were not statistically significant (Tukey's multiple-comparison test). Notably, treatment with VRT-532 (5 M ϫ 20 min) did not elicit any detectable phosphorylation of R-D in this assay (Fig. 1, A-D) and was significantly less that UC CF -152 (P Ͻ 0.05). Further analysis of the UC CF -152 induced phosphorylation of the R-D confirmed that it occurred rapidly (within 2 min of compound exposure, Fig. 1E ). Furthermore, pretreatment with H89 reduced the UC CF -152 induced R-D phosphorylation (Fig. 1D) . This suggested that, like forskolin, UC CF -152 stimulated phosphorylation of the R-D is mediated in part through a PKA-mediated phosphorylation event. However, unlike forskolin, UC CF -152 did not act to stimulate the production of detectable global or perimembranous cAMP in these cells ( Fig. 1F and Supplemental Fig. S1 , respectively; the online version of this article contains supplemental data), and did not directly activate human PKA (Supplemental Fig. S2 ). R-D phosphorylation by these compounds was not due to changes in protein phosphatase 2A (PP2A) activity or PDE inhibition. Several protein phosphatases have been implicated in CFTR regulation, and PP2A in particular is thought to be relevant to the CFTR microdomain (38, 42) . When PP2A activity was measured via colorimetric reading of phosphate cleavage from a PP2A-specific peptide, neither VRT-532 nor UC CF -152 altered PP2A activity compared with the positive control inhibitor (20 M cantharidin and 20 nM microcystin LR) (P Ͻ 0.0001; Supplemental Fig. S3 ). Similarly, inhibition of PDE4D was not observed with either agent (Supplemental Fig. S4 ). Finally, we determined that VRT-532 did not shift the dose-response of R-D phosphorylation by forskolin, demonstrating that VRT-532 did not potentiate R-D phosphorylation, whereas UC CF -152 increased phosphorylation in the presence of all concentrations of forskolin (Supplemental Fig. S5) . Impact of UC CF -152 and VRT-532 on CFTR-dependent short-circuit current. Because these two compounds demonstrated different effects on R-D phosphorylation, we next compared the functional activity of UC CF -152 and VRT-532 by using the I sc studies in polarized epithelial monolayers. We first employed the CFBE41o Ϫ cell line, an SV-40 transformed CF bronchial epithelial cell line that has undetectably low levels of expression of endogenous F508del-CFTR. By using this cell line, I sc can be compared with stable heterologous expression of WT-CFTR, F508del-CFTR, or other mutant forms of CFTR (5, 15) . We compared the effects of the UC CF -152 and VRT-532 alone and after sequential addition of submaximal forskolin (2 M), which activates CFTR through R-D phosphorylation, and genistein (50 M), which acts primarily on the gating mechanism of surface-expressed CFTR. Submaximal doses of the cAMP agonist forskolin were selected to allow additional detectable activation with other compounds and better discrimination of divergent compound mechanisms. Representative tracings are shown in Fig. 2A , and the summary data are shown in Fig. 2 , B-E.
WT-CFTR. Although addition of either VRT-532 or UC CF -152 resulted in an I sc increase greater than vehicle control ( Fig.  2A, left, and B) , UC CF -152 induced activity was significantly greater than that induced by VRT-532 (P Ͻ 0.05) and approached the response induced by forskolin alone (Fig. 2C , vehicle pretreatment). Prior addition of VRT-532 enhanced I sc induced by subsequent addition of forskolin addition (e.g., it "potentiated" cAMP activation of the channel) (Fig. 2C) . In contrast, cells pretreated with UC CF -152 showed minimal additional I sc with forskolin (Fig. 2C ). Subsequent addition of genistein did not result in a further increase in the UC CF -152 or VRT-532-treated CFBE/WT-CFTR cells (Fig. 2D) . These findings suggest that UC CF -152 primarily activated CFTR in a fashion redundant with forskolin, whereas VRT-532 potentiated forskolin mediated activation and only modestly activated CFTR alone.
In biochemical studies both UC CF -152 treatment and forskolin, but not VRT-532, stimulated the phosphorylation of CFTR R-D, an effect reduced by H89. We therefore investigated the effects of H89 pretreatment on the I sc of CFBE/WT-CFTR cells treated with CFTR modulators (Fig. 3) . Pretreatment with H89 resulted in a significant reduction (71%, P Ͻ 0.05 for UC CF -152 vs. vehicle) in UC CF -152 stimulated I sc . In contrast, H89 reduced VRT-532-induced I sc by only 35% (P ϭ not significant for VRT-532 vs. vehicle). These results indicate that the mechanism by which UC CF -152 enhances CFTR activity overlaps with the mechanism of action of forskolin and is largely dependent on PKA phosphorylation. They also suggest that the mechanism by which VRT-532 enhances CFTR activity differs substantially from the mechanism underlying UC CF -152 and forskolin.
F508del-CFTR. To test whether differences between UC CF -152 and VRT-532 were also observed in clinically relevant CFTR mutants, we next examined the agents' impact on F508del-CFTR activity following temperature rescue to the cell surface by preincubation at 27°C (R-F508del-CFTR). Forskolin treatment of temperature-rescued CFBE41o Ϫ cells (CFBE/R-F508del-CFTR) indicated that these cells were relatively resistant to cAMP stimuli (Fig. 2, A, right, and B-E) , whereas genistein robustly enhanced I sc as previously described (5), indicative of the gating defect present in R-F508del-CFTR. Both VRT-532 (13.5 A/cm 2 ) and UC CF -152 (7.3 A/cm 2 ) increased I sc in the CFBE/R-F508del-CFTR (Fig. 2B) . The compounds in combination elicited a synergistic response, further suggesting divergent mechanisms. Notably, the responses to subsequent addition of forskolin differed substantially. The addition of forskolin did not enhance I sc in the UC CF -152-treated cells, regardless of the presence or absence of concurrent VRT-532, whereas I sc was strongly augmented by forskolin in cells pretreated with VRT-532 alone (Fig. 2C) . In addition, total stimulated I sc (modulator ϩ forskolin ϩ genistein) in UC CF -152-treated cells was 42.2 A/ cm 2 , 48.5 A/cm 2 for cells pretreated with VRT-532 and UC CF -152 simultaneously, and 39.4 A/cm 2 in vehicle (vehicle ϩ forskolin ϩ genistein), whereas total stimulated I sc for VRT-532-pretreated cells was 49.4 A/cm 2 (P Ͻ 0.05 vs. vehicle pretreated) (Fig. 2E) . These results indicated that VRT-532, but not UC CF -152, potentiated I sc activation by forskolin in the F508del-CFTR-expressing cells, overcoming the CFBE/ R-F508del-CFTR defect in cAMP-dependent activation seen in vehicle-treated cells.
Some elements of CFTR activation have been found to be dependent on cell type. FRT cells have been used in several high-throughput screening programs and studies to compare modulator effects (17) . Expanding on results seen in the CFBE41o Ϫ model, we evaluated the impact of modulator compounds on stably expressed CFTR in FRT cells grown in polarizing conditions. In this setting we examined two clinically relevant CFTR mutations: R-F508del-CFTR and G551D-CFTR. In FRT/R-F508del cells (Fig. 4, left) , UC CF -152 again activated I sc (Fig. 4A ) but had no effect on forskolin-dependent I sc (Fig. 4B) . In contrast, VRT-532 had minimal detectable effect on I sc upon direct addition (Fig. 4A ) but strongly potentiated forskolin-dependent I sc (Fig. 4B) . Similarly, total current (modulator ϩ forskolin) was augmented by VRT-532, and less so by UC CF -152 treatment (Fig. 4C) .
G551D-CFTR.
We then tested the effects of modulators on G551D-CFTR, a surface mutant of CFTR that is associated with a severe gating defect (Fig. 4, right) (49) . Again UC CF -152 enhanced I sc upon acute addition (Fig. 4A ) but did not potentiate cAMP-dependent CFTR activation (Fig. 4B) . Potentiation of forskolin was observed in the FRT/G551D-CFTR cells treated with VRT-532 (Fig. 4B) , reflecting the propensity of VRT-532, but not UC CF -152, to rescue cAMP-induced I sc in the setting of a CFTR gating mutation. Both agents significantly increased total I sc , although VRT-532-treated cells had greater total activated current ( Fig. 4C ; 5.5 Ϯ 0.7 A/cm 2 VRT-532 vs. 3.7 Ϯ 0.8 A/cm 2 UC CF -152, P Ͻ 0.05).
Modulators in combination with F508del-CFTR correctors.
To investigate the combined use of small molecule correctors of F508del-CFTR with rapidly acting CFTR modulators, as proposed for clinical testing, we compared the effects of the compounds on cells in which the F508del-CFTR had been rescued to the cell surface by treatment with the small molecule corrector of misprocessing Corr-4a (Fig. 5) (25) . Corr-4a alone did not overcome the block of forskolin-mediated activation of CFBE/F508del-CFTR cells that is characteristic of these cells, although the agent did increase I sc stimulated by the combination of genistein and forskolin (7.5 Ϯ 1.1 A/cm 2 37°C control, 11.0 Ϯ 1.6 A/cm 2 Corr-4a treated, P Ͻ 0.01, n ϭ 14 per condition). Similar to the results obtained in the setting of low-temperature rescued CFTR, VRT-532 significantly en- hanced forskolin-mediated activation in cells in Corr-4a-treated cells whereas UC CF -152 pretreatment had a minimal effect on forskolin-stimulated Cl Ϫ transport (Fig. 5A ). VRT-532 also significantly enhanced forskolin-mediated activation in both CFBE41o
Ϫ and FRT cells in which F508del had not been rescued to the cell surface by low-temperature growth (37°C control), likely reflecting low levels of surface localized F508del-CFTR under basal conditions in these cells.
Effect of VX-770 on R-D phosphorylation.
Recent clinical testing has demonstrated that the CFTR potentiator VX-770 shows significant promise for the treatment of G551D-CFTR, providing partial restoration of chloride conductance across both nasal epithelia and sweat glands in human subjects (1) . Although the precise mechanism of action remains to be defined (30), VX-770 strongly potentiates forskolin-dependent current in G551D-CFTR monolayers (40) . Assessment of this CFTR gating potentiator demonstrated minimal phosphorylation of the R-D (Fig. 6 ), similar to that seen with VRT-532. These data indicate that, like VRT-532, VX-770 potentiates CFTR activity without direct impact on R-D phosphorylation.
DISCUSSION
Here we describe two distinct mechanisms underlying acute CFTR activation by CFTR modulators recently identified in high-throughput screening programs. The compound UC CF -152 (an isoxazole) induced robust phosphorylation of the R-D and increased I sc in WT-, R-F508del-, and G551D-CFTR cell monolayers in a fashion that was relatively sensitive to PKA inhibition but did not increase (and in some cases reduced) subsequent cAMP-mediated activation of CFTR by forskolin. In contrast, VRT-532 (a pyrazole) did not induce phosphorylation of the R-D and activated CFTR through a mechanism that was relatively independent of H89 blockade. Potentiation of downstream forskolin-dependent activation was observed following addition of VRT-532 in F508del-, G551D-, and WT-CFTR cell monolayers. These data indicate that UC CF -152 is most appropriately classified as an activator of Cl Ϫ conductance, increasing I sc regardless of endogenous cAMP-dependent signaling, whereas VRT-532 primarily potentiates cAMPmediated activation. Consistent with this characterization, the two agents exhibit distinctly different effects on R-D phosphorylation status and synergistically increase I sc in R-F508del-CFTR monolayers, indicating important functional implications of the mechanistic divergence at the crucial R-D phosphorylation step in CFTR activation.
The present studies demonstrate that UC CF -152 induces potent and rapid phosphorylation of the R-D. The specific UC CF -152 target(s) responsible for this modification is not yet known. However, the rapid time course, combined with recent evidence regarding the kinetics of individual R-D phosphorylation sites (27) , may allow future speculation of the specific sites relevant to UC CF -152 activity. Further work to identify the phosphorylated residues involved, combined with recent efforts to elucidate the impact of individual phosphorylation sites on CFTR conformational changes during gating, may expand our understanding of both CFTR gating and the impact of UC CF -152. For example, of the phosphorylation sites within the R-D known to be relevant to endogenous CFTR activation, some (including S768) are thought to be inhibitory and may address the impact of UC CF -152 on total activation in some cell types (e.g., WT-CFTR CFBE41o Ϫ ). Additionally, one phosphorylation site, S422, lies outside the region encompassed by the R-D assay, in a portion of CFTR known as the regulatory insertion of NBD1. As shown by Sammelson et al. (32) and confirmed by our study, UC CF -152 did not increase levels of cellular cAMP, nor did it directly activate PKA, indicating a mechanism distinct from CFTR activation by adenylate cyclase. Similarly, neither VRT-532 nor UC CF -152 inhibited PP2A or PDE4 in a cell-free system. Evidence suggests these are the most relevant protein phosphatases and phosphodiesterases to CFTR microenvironment regulation, but other isoforms may be considered in further work. Enhancement of R-D susceptibility to phosphorylation, or activation of PKC (34) (an alternative CFTR phosphorylation pathway only partially susceptible to H89 blockade) are potential pathways through which CFTR may be phosphorylated by UC CF -152. Alternatively, because phosphodiesterases of the PDE4 family are thought to be compartmentally active in epithelia (4), measurements of cAMP in closer proximity to CFTR may be required to discern a local effect. Experiments to examine whether blockade of these candidate pathways also inhibit R-D phosphorylation by UC CF -152 will be necessary to distinguish among these possibilities.
Wang et al. (43) demonstrated that F508del-CFTR may be a poorer substrate for PKA phosphorylation than WT-CFTR, since CFTR activity in an isolated cell-membrane patch in the presence of low levels of PKA exhibits gating behavior similar to F508del-CFTR. Our data suggest that normal regulation of the mutant channel can be restored by a compound capable of pharmacologically potentiating endogenous signaling and does not require phosphorylation by the compound itself. It should be noted that VRT-532 or VX-770 may induce phosphorylation events below the resolution of the R-D assay, although such events would be expected to be evident with application of the phosphorylation-specific antibody. Moreover, these observations suggest for the first time that a potentiator (VRT-532) can rescue cAMP-dependent activation in CFBE41o Ϫ cells, an airway cell type representative of most primary F508del bronchial epithelial cells, in that it is refractory to cAMP-mediated stimulation of R-F508delCFTR through physiological receptor-mediated pathways (5). These findings are germane and contribute to previous reports of the activity of VRT-532 and VX-770 in primary epithelial cells (41) . Furthermore, the observation that augmentation of the forskolinstimulated Cl Ϫ current in uncorrected F508del-CFTR expressing CFBE41o
Ϫ cells was detectable following application of VRT-532 [an effect not elicited by flavonoid CFTR modulators (5)], provides evidence that low levels of F508del-CFTR at the cell surface can be detected in this model system, as has also been suggested in some human studies of primary human cells (13, 35, 41) .
Our findings suggest that the mechanism of action of VRT-532 is downstream of R-D phosphorylation. CFTR active compounds have been previously postulated to interact directly with the NBDs, including the well-studied flavonoid genistein (44) . In this study, unlike VRT-532, genistein induced highly variable levels of R-D phosphorylation (Fig. 1A) and, in both this study (Fig. 2) and others, failed to restore cAMP response 18, 23) and that proper NBD conformation can have an impact on channel sensitivity to R-D activation by PKA (5, 43) . For example, deletion of phenylalanine 508 has been shown by macropatch analysis to attenuate phosphorylation-dependent activation of CFTR (43), a finding confirmed in polarized epithelial cells (5) . It is plausible that CFTR interactions with VRT-532 may increase the sensitivity of CFTR to both endogenous and agonist-stimulated cAMP signaling, effectively resolving the defective cAMP signaling response seen in F508del-CFTR expressing cells (Fig. 2) . That VRT-532 did not shift the forskolin dose-response of the R-D assay indicates that these interactions between VRT-532 and CFTR, whether direct or indirect, are outside of the R-D.
It bears noting that the mechanistic basis of each compound appears to be closely related to the HTS method through which they were identified. VRT-532 was identified by use of a HTS system that measured activity in F508del-CFTR following application of both potentiator and forskolin (10 M) whereas UC CF -152 and UC CF -029 (which also increased R-D phosphorylation) were identified in WT cells in the absence of addition of forskolin (41) . This explains why VRT-532 increases CFTR sensitivity to cAMP signaling (e.g., a potentiator), whereas UC CF -152 functions as a direct activator.
Our results indicate that combined use of an F508del-CFTR processing corrector and CFTR potentiator of endogenous gating mechanisms represents a feasible approach to overcoming F508del-CFTR defects. VRT-532 retains its property as a CFTR potentiator in the setting of processing restoration by either low temperature or the small molecule corrector, Corr4a. Whereas some primary F508del bronchial epithelial cells exhibit intact cAMP-dependent activation [likely due to celltype specific aspects (6)], previous studies in our laboratory (5) and others (2, 43) provide evidence that a F508del-CFTR potentiator will likely be needed to produce clinically relevant levels of CFTR activity in the airways of subjects harboring F508del, unless the pharmacological approach employed to correct the processing defect also inherently confers wild-type gating of the mutant channel in sufficient numbers.
An improved understanding of the mechanisms of action of newly described acute CFTR modulators is essential for the design of congeners, the identification of agents best suited for use in combination with correctors of F508del-CFTR processing, or for application to particular CF mutations. The results of our studies suggest that there are at least two classes of acute CFTR modulators characterized by the effects on R-D phosphorylation and that these results distinguished activation (as opposed to potentiation) of CFTRmediated currents and predicted potential for synergy between agents. Results reported for the CFTR potentiator VX-770 on cells (40) and in CF patients carrying the G551D-CFTR mutation (1) combined with our studies indicate that augmentation of R-D phosphorylation is not required to confer rescue of mutant CFTR channel activity in the clinic. Analysis of R-D phosphorylation may be useful to categorize acute CFTR modulators and help distinguish the mechanistic basis underlying their effects.
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